{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:31:25Z","timestamp":1787671885933,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05508-1","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:32:01Z","timestamp":1779953521000},"page":"17767-17780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination treatment with mitoxantrone and doxorubicin induces multidrug resistance in Ewing Sarcoma CDX reporter xenografts"],"prefix":"10.1007","volume":"399","author":[{"given":"Kirtana","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabitha","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithra","family":"Ayyadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithik Roshan","family":"Rajasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Murhekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"5","key":"5508_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1172\/JCI117910","volume":"95","author":"M Alvarez","year":"1995","unstructured":"Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1\/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Investig 95(5):2205\u20132214","journal-title":"J Clin Investig"},{"issue":"11","key":"5508_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708943","volume":"18","author":"NM Ayoub","year":"2021","unstructured":"Ayoub NM (2021) Novel combination therapies for the treatment of solid cancers. Front Oncol 18(11):708943","journal-title":"Front Oncol"},{"key":"5508_CR3","doi-asserted-by":"crossref","unstructured":"Baeder DY, Yu G, Hoz\u00e9 N, Rolff J, Regoes RR (2016) Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models.\u00a0Philos Trans R Soc Lond B Biol Sci\u00a0\u00a0371(1695):20150294","DOI":"10.1098\/rstb.2015.0294"},{"issue":"9","key":"5508_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4161\/cbt.3.9.1101","volume":"3","author":"EK Baker","year":"2004","unstructured":"Baker EK, El-Osta A (2004) MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther 3(9):819\u2013824","journal-title":"Cancer Biol Ther"},{"issue":"54","key":"5508_CR5","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1038\/sj.onc.1208955","volume":"24","author":"EK Baker","year":"2005","unstructured":"Baker EK, Johnstone RW, Zalcberg JR, El-Osta A (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24(54):8061\u20138075","journal-title":"Oncogene"},{"issue":"7","key":"5508_CR6","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-11-1590","volume":"18","author":"KG Chen","year":"2012","unstructured":"Chen KG, Sikic BI (2012) Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18(7):1863\u20131869","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5508_CR7","doi-asserted-by":"publisher","DOI":"10.1515\/jib-2010-116","volume":"7","author":"SJ Cockell","year":"2010","unstructured":"Cockell SJ, Weile J, Lord P, Wipat C, Andriychenko D, Pocock M, Wilkinson D, Young M, Wipat A (2010) An integrated dataset for in silico drug discovery. J Integr Bioinform 7(3):116","journal-title":"J Integr Bioinform"},{"issue":"9","key":"5508_CR8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","volume":"90","author":"RM Damiani","year":"2016","unstructured":"Damiani RM, Moura DJ, Viau CM, Caceres RA, Henriques JA, Saffi J (2016) Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol 90(9):2063\u20132076","journal-title":"Arch Toxicol"},{"issue":"1","key":"5508_CR9","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/npjsba.2016.15","volume":"2","author":"Q Duan","year":"2016","unstructured":"Duan Q, Reid SP, Clark NR, Wang Z, Fernandez NF, Rouillard AD, Readhead B, Tritsch SR, Hodos R, Hafner M, Niepel M (2016) L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Systems Biology and Applications 2(1):16015","journal-title":"NPJ Systems Biology and Applications"},{"issue":"2","key":"5508_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/med.21364","volume":"36","author":"BJ Evison","year":"2016","unstructured":"Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2016) Mitoxantrone, more than just another topoisomerase II poison. Med Res Rev 36(2):248\u2013299","journal-title":"Med Res Rev"},{"issue":"6","key":"5508_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","volume":"40","author":"HH Fiebig","year":"2004","unstructured":"Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40(6):802\u2013820","journal-title":"Eur J Cancer"},{"issue":"27","key":"5508_CR12","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33(27):3036\u20133046","journal-title":"J Clin Oncol"},{"issue":"1","key":"5508_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TG Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald TG, Cidre-Aranaz F, Surdez D, Tomazou EM, de \u00c1lava E, Kovar H, Sorensen PH, Delattre O, Dirksen U (2018) Ewing Sarcoma Nature Reviews Disease Primers 4(1):5","journal-title":"Ewing Sarcoma Nature Reviews Disease Primers"},{"key":"5508_CR14","doi-asserted-by":"crossref","unstructured":"Hwangbo H, Patterson S, Dai A, Plana D, Palmer AC (2023) Additivity predicts the clinical efficacy of most approved combination therapies for advanced cancer. Cancer Res 4;83(7_Supplement):5718","DOI":"10.1158\/1538-7445.AM2023-5718"},{"key":"5508_CR15","doi-asserted-by":"crossref","unstructured":"Ianevski A, Giri AK, Aittokallio T (2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res 5;50(W1):W739\u201343","DOI":"10.1093\/nar\/gkac382"},{"issue":"1","key":"5508_CR16","volume":"2014","author":"K Katayama","year":"2014","unstructured":"Katayama K, Noguchi K, Sugimoto Y (2014) Regulations of P\u2010glycoprotein\/ABCB1\/MDR1 in human cancer cells. New J Sci 2014(1):476974","journal-title":"New J Sci"},{"issue":"2","key":"5508_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1158\/1541-7786.MCR-20-0651","volume":"19","author":"JC Martin","year":"2021","unstructured":"Martin JC, Hoegel TJ, Lynch ML, Woloszynska A, Melendy T, Ohm JE (2021) Exploiting replication stress as a novel therapeutic intervention. Mol Cancer Res 19(2):192\u2013206","journal-title":"Mol Cancer Res"},{"issue":"6","key":"5508_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jphp.12539","volume":"68","author":"AM Meredith","year":"2016","unstructured":"Meredith AM, Dass CR (2016) Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol 68(6):729\u2013741","journal-title":"J Pharm Pharmacol"},{"issue":"23","key":"5508_CR19","first-page":"38022","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination Therapy in Combating Cancer Oncotarget 8(23):38022","journal-title":"Combination Therapy in Combating Cancer Oncotarget"},{"issue":"2","key":"5508_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00210-020-01982-3","volume":"394","author":"A Natarajan","year":"2021","unstructured":"Natarajan A, Ramachandran B, Gopisetty G, Jayavelu S, Sundersingh S, Rajkumar T (2021) Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft. Naunyn Schmiedebergs Arch Pharmacol 394(2):361\u2013371","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"online first","key":"5508_CR21","first-page":"402","volume":"3","author":"E Pagano","year":"2021","unstructured":"Pagano E, Bergamo A, Carpi S, Donnini S, Notarbartolo di Villarosa M, Serpe L, Lisi L (2021) Preclinical models in oncological pharmacology: limits and advantages. Pharmadvances 3(online first):402\u201320","journal-title":"Pharmadvances"},{"issue":"10","key":"5508_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/cmdc.201300233","volume":"8","author":"IK Pajeva","year":"2013","unstructured":"Pajeva IK, Sterz K, Christlieb M, Steggemann K, Marighetti F, Wiese M (2013) Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P\u2010glycoprotein. ChemMedChem 8(10):1701\u20131713","journal-title":"ChemMedChem"},{"issue":"1","key":"5508_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08880018.2011.622034","volume":"29","author":"J Potratz","year":"2012","unstructured":"Potratz J, Dirksen U, J\u00fcrgens H, Craft A (2012) Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 29(1):1\u20131","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"5508_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.toxrep.2016.03.001","volume":"1","author":"B Ramachandran","year":"2016","unstructured":"Ramachandran B, Jayavelu S, Murhekar K, Rajkumar T (2016) Repeated dose studies with pure epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia. Toxicol Rep 1(3):336\u2013345","journal-title":"Toxicol Rep"},{"key":"5508_CR25","doi-asserted-by":"crossref","unstructured":"Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47","DOI":"10.1093\/nar\/gkv007"},{"key":"5508_CR26","unstructured":"Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, et al (2011) Inflammatory gene profiling of Ewing sarcoma family of tumors (set B) . NCBI Gene Expression Omnibus. Accession No. GSE17674. Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE17674. Accessed 26 May 2026"},{"issue":"4","key":"5508_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00059-011-3470-3","volume":"36","author":"Y Shi","year":"2011","unstructured":"Shi Y, Moon M, Dawood S, McManus B, Liu PP (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36(4):296\u2013305","journal-title":"Herz"},{"issue":"2","key":"5508_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/107327480301000207","volume":"10","author":"H Thomas","year":"2003","unstructured":"Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10(2):159\u2013165","journal-title":"Cancer Control"},{"issue":"3","key":"5508_CR29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1172\/JCI130809","volume":"130","author":"MS Williams","year":"2020","unstructured":"Williams MS, Amaral FM, Simeoni F, Somervaille TC (2020) A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia. J Clin Investig 130(3):1217\u20131232","journal-title":"J Clin Investig"},{"issue":"7","key":"5508_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202100029","volume":"43","author":"PP Yee","year":"2021","unstructured":"Yee PP, Li W (2021) Tumor necrosis: a synergistic consequence of metabolic stress and inflammation. BioEssays 43(7):2100029","journal-title":"BioEssays"},{"issue":"3","key":"5508_CR31","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.18632\/oncotarget.12566","volume":"8","author":"H Yu","year":"2016","unstructured":"Yu H, Ge Y, Guo L, Huang L (2016) Potential approaches to the treatment of Ewing\u2019s sarcoma. Oncotarget 8(3):5523","journal-title":"Oncotarget"},{"issue":"8","key":"5508_CR32","first-page":"3394","volume":"61","author":"Z Zhou","year":"2001","unstructured":"Zhou Z, Jia SF, Hung MC, Kleinerman ES (2001) E1A sensitizes HER2\/neu-overexpressing Ewing\u2019s sarcoma cells to topoisomerase II-targeting anticancer drugs. Can Res 61(8):3394\u20133398","journal-title":"Can Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05508-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:03:24Z","timestamp":1787670204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05508-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5508"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05508-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animals used in this study were sourced from Hylasco Biotechnology (India) Pvt. Ltd. (Technology Licensee of Charles River Laboratory, USA). Animal experiments were carried out with prior approval from the Institutional Animal Ethics Committee of Cancer Institute (W.I.A), Adyar, Chennai, India, with project approval numbers (IAEC approval no. CIWIA20230604).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}